在卵母细胞捐赠者中使用枸橼酸克罗米芬促性腺激素释放激素拮抗剂方案时,5天与7天停用避孕药间隔的重要性:一项前瞻性队列研究
这项前瞻性队列研究纳入卵母细胞捐赠者,比较停用避孕药5天(D5组,42名)与7天(D7组,50名)后开始使用可丽康芬α的拮抗剂方案。D7组总促性腺激素剂量、刺激时长、总药物费用和注射次数显著低于D5组,获卵总数无差异。
要点
- 停用避孕药7天后开始可丽康芬α较5天显著降低促性腺激素总剂量。
- D7组刺激时长和注射次数显著少于D5组,获卵总数无显著差异。
- D7组药物总费用显著低于D5组。
核心结论
- 服用避孕药超过22天后,将停用间隔延长至7天可显著减少促性腺激素总剂量、刺激时长、药物总费用和注射次数。
研究设计与样本
- 前瞻性队列研究,纳入卵母细胞捐赠者,D5组42名,D7组50名,均接受可丽康芬α联合促性腺激素释放激素拮抗剂方案。
主要发现
- D5组平均(标准差)额外重组促卵泡激素总剂量为659(452)IU,D7组为459(356)IU(P=0.022)。
- D5组刺激时长显著长于D7组(P=0.002)。
- D7组总注射次数为9.8(3.2)次,显著低于D5组的11.9(3.9)次(P=0.004)。
- D5组药物总费用显著高于D7组(P=0.015)。
- 两组获卵总数无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this prospective cohort study, oocyte donors were recruited prospectively and assigned to receive corifollitropin alfa: 5 days after pill discontinuation (group D5; 42 donors), or 7 days after pill discontinuation (group D7; 50 donors) in a gonadotrophin-releasing hormone antagonist protocol. Fixed additional daily doses of 200 IU recombinent FSH (rFSH) were started after 7 days of corifollitropinalfa, until triggering. No significant differences in basal characteristics were observed between both groups. In group D5, mean (SD) total additional rFSH dose was 659 (452) IU; in group D7, total rFSH dose was 459 (356) IU (P = 0.022). Duration of stimulation was significantly longer in group D5 compared with group D7 (P = 0.002). No differences were found in total number of oocytes obtained. Total number of injections was significantly lower in group D7 compared with group D5 (9.8 [3.2] versus 11.9 [3.9], respectively; P = 0.004). Total cost of medication used for donor treatment was significantly higher in group D5 than in group D7 (P = 0.015). After more than 22 days of pill-taking, extending the pill-free interval to 7 days significantly reduces the total dose of gonadotrophins, duration of stimulation, total cost of medication and total number of injections.
引用
- Pérez-Calvo A, Martínez F, Blockeel C, et al. Importance of a 5- versus 7-day pill-free interval in a GnRH antagonist protocol using corifollitropin alfa: a prospective cohort study in oocyte donors. Reprod Biomed Online. 2017. PMID: 28797743. doi:10.1016/j.rbmo.2017.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。